CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed
Drug / intervention
The GlucoWatch® G2™ Biographer (GW2B) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00069537
NCT00069537Phase 4Completed
CompareCT.gov

DirecNet Inpatient Study to Test the Accuracy of Continuous Blood Glucose Monitoring Devices in Children With Type 1 Diabetes

Jaeb Center for Health Research·interventional·Posted Sep 30, 2003·Updated Sep 5, 2016

In Brief

A Phase 4 clinical trial evaluating The GlucoWatch® G2™ Biographer (GW2B) and The Continuous Glucose Monitoring System (CGMS™) for Diabetes Mellitus, Insulin-Dependent. Completed, across 6 sites.

Detailed Summary

Good control of blood glucose levels is important in preventing complications from diabetes. This study assessed the accuracy and reliability of two FDA-approved continuous glucose monitors, the Continuous Glucose Monitoring System (CGMS) and the GlucoWatch G2 Biographer (GW2B), in children with type 1 diabetes mellitus (T1DM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Insulin-Dependent
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 4CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 30, 2003
Enrollment StartMay 1, 2002
Study CompletionNov 1, 2002
TodayJul 2, 2026
Posted 22.8 years ago

Interventions

The GlucoWatch® G2™ Biographer (GW2B)device

The Continuous Glucose Monitoring System (CGMS™)device